Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913986 | 0.96 | ALDH1A1 (0.68) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| SCHEMBL5465603 | 0.84 | ALDH1A1 (0.57) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| SCHEMBL5450984 | 0.84 | ALDH1A1 (0.57) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| SCHEMBL3397070 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| SCHEMBL13658120 | 0.77 | KDM4E (0.68) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| SCHEMBL2688221 | 0.77 | ALDH1A1 (1.00) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| SCHEMBL5823313 | 0.77 | ALDH1A1 (0.68) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| SCHEMBL7455441 | 0.76 | KDM4E (0.68) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| SCHEMBL8290416 | 0.76 | ALDH1A1 (1.00) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| SCHEMBL12632686 | 0.76 | KDM4E (0.69) | ALDH1A1KMT2AKDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060019952-A1 | Anti-viral therapeutics | ELIXIR PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-20050250794-A1 | Use of heterocyclic compounds such as thiophenes, 1,2,4-triazoles and benzoxazoles; as inhibitors of deacetylase SirT1 protein sirtuin to treat neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders such as diabetes | ELIXIR PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250794-A1 | Use of heterocyclic compounds such as thiophenes, 1,2,4-triazoles and benzoxazoles; as inhibitors of deacetylase SirT1 protein sirtuin to treat neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders such as diabetes | SIRT1, SIRT3, SIRT4 | ALDH1A1 347/4885KMT2A 994/4885KDM4E 814/4885 |
| US-20060019952-A1 | Anti-viral therapeutics | CD4, MAVS, HAVCR2 | ALDH1A1 1387/4885KMT2A 3919/4885KDM4E 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.